Invesco Ltd. Purchases 27,291 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• Invesco Ltd. increased its holdings in Eyepoint Pharmaceuticals by 174.3%, acquiring an additional 27,291 shares and totaling 42,948 shares valued at $233,000 as of the latest SEC filing.
• Eyepoint Pharmaceuticals reported a quarterly loss of ($0.85) EPS, falling short of the consensus estimate of ($0.67), while total revenue for the quarter was $5.33 million, below expectations.
• The stock has a market capitalization of approximately $965.71 million, with a one-year price range between $3.91 and $14.37 per share.

Invesco Ltd. grew its position in shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 174.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,948 shares of the company's stock after purchasing an additional 27,291 shares during the quarter. Invesco Ltd. owned approximately 0.06% of Eyepoint Pharmaceuticals worth $233,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. California State Teachers Retirement System increased its position in shares of Eyepoint Pharmaceuticals by 3.8% during the 4th quarter. California State Teachers Retirement System now owns 48,614 shares of the company's stock valued at $362,000 after purchasing an additional 1,797 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Eyepoint Pharmaceuticals by 12.7% during the first quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after buying an additional 1,877 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Eyepoint Pharmaceuticals by 5.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 71,238 shares of the company's stock valued at $531,000 after buying an additional 3,657 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Eyepoint Pharmaceuticals by 3.2% during the fourth quarter. Wellington Management Group LLP now owns 177,316 shares of the company's stock valued at $1,321,000 after buying an additional 5,552 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC grew its stake in shares of Eyepoint Pharmaceuticals by 48.6% during the first quarter. Cyndeo Wealth Partners LLC now owns 25,250 shares of the company's stock valued at $137,000 after buying an additional 8,260 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors.

Eyepoint Pharmaceuticals Price Performance

NASDAQ EYPT opened at $14.01 on Monday. The stock has a market capitalization of $965.71 million, a PE ratio of -5.23 and a beta of 1.93. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $14.37. The business's 50-day moving average is $10.71 and its 200 day moving average is $8.07.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). The business had revenue of $5.33 million during the quarter, compared to the consensus estimate of $6.82 million. Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%. As a group, equities research analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

Analyst Ratings Changes

EYPT has been the topic of a number of recent research reports. Mizuho reduced their price objective on Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a research note on Friday, May 16th. Royal Bank Of Canada initiated coverage on Eyepoint Pharmaceuticals in a research note on Tuesday, June 17th. They set an "outperform" rating and a $28.00 price objective on the stock. Chardan Capital reaffirmed a "buy" rating and set a $27.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Finally, HC Wainwright upped their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $26.86.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.